Polymyositis and dermatomyositis secondary prevention

Polymyositis and dermatomyositis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Polymyositis and dermatomyositis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Polymyositis and dermatomyositis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Polymyositis and dermatomyositis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Polymyositis and dermatomyositis secondary prevention
CDC on Polymyositis and dermatomyositis secondary prevention
Polymyositis and dermatomyositis secondary prevention in the news
Blogs on Polymyositis and dermatomyositis secondary prevention
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Polymyositis and dermatomyositis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

• Effective measures for the secondary prevention of polymyositis and dermatomyositis include:
  • Assessment for malignancy initially and annually for three years